KLRS
NASDAQ · Biotechnology
Kalaris Therapeutics Inc
$6.00
+0.23 (+3.99%)
Open$6.14
Previous Close$5.77
Day High$6.18
Day Low$5.66
52W High$11.88
52W Low$2.14
Volume—
Avg Volume61.2K
Market Cap122.01M
P/E Ratio—
EPS$-4.27
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+281.5% upside
Current
$6.00
$6.00
Target
$22.89
$22.89
$19.41
$22.89 avg
$38.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |
| Rev Growth | +16.8% | +12.7% | +4.6% |
| Debt/Equity | 0.77 | 0.70 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |